Search clinical trials for: REGN3500

Total 34 results

Regeneron Pharmaceuticals
Sanofi

Terminated

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Hungary, Korea, Republic of, Germany, Japan, Poland, Australia, Canada, Czechia, Spain, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects

Healthy Volunteers

Belgium
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma

Asthma | Moderate Asthma

United Kingdom
Regeneron Pharmaceuticals

Completed

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

Hypertriglyceridemia

United States
Regeneron Pharmaceuticals

Completed

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

Metabolic Disorders

United States
Regeneron Pharmaceuticals

Completed

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

Severe Hypertriglyceridemia (sHTG)

United States, Canada, Italy, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Terminated

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Korea, Republic of, Belgium, Czechia, Germany, Poland, Spain
Regeneron Pharmaceuticals

Completed

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Australia, Austria, Netherlands, Taiwan, Ukraine
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Netherlands, Australia, Austria, Canada, France, Greece, Italy, Japan, South Africa, Ukraine
Regeneron Pharmaceuticals

Completed

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

Healthy Volunteers

United States
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

Bronchiectasis

Poland, France, Germany, Italy, United Kingdom, Turkey, Greece, Argentina, United States, China, Czechia, Brazil, Chile, Japan, Canada, Denmark, Israel, Netherlands, Spain, Taiwan
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD (AERIFY-4)

Chronic Obstructive Pulmonary Disease

China, Argentina, Bulgaria, Chile, Georgia, India, Poland, Brazil, Canada, Estonia, France, Germany, Mexico, Spain, United Kingdom, Turkey, United States, South Africa, Hungary, Greece, Israel, Japan, Czechia, Norway, Portugal, Slovakia, Italy and more
Regeneron Pharmaceuticals

Completed

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Netherlands, South Africa, Australia, Austria, Canada, Czechia, France, Greece, Italy, Japan, Ukraine
Regeneron Pharmaceuticals

Available

Compassionate Use of Evinacumab

Pediatric Homozygous Familial Hypercholesterolemia (HoFH) | Severe Hypertriglyceridemia (HTG) | Dysbetalipoproteinemia (DBL)
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD (AERIFY-3)

Chronic Obstructive Pulmonary Disease

Denmark, Belgium, United States, Brazil, Germany, Netherlands, United Kingdom
Regeneron Pharmaceuticals

Terminated

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

Hypertriglyceridemia

United States, Germany, Netherlands, Canada
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)

Chronic Obstructive Pulmonary Disease

Portugal, Chile, South Africa, Turkey, Korea, Republic of, Israel, Hungary, Mexico, Spain, Germany, Netherlands, Russian Federation, Japan, Czechia, Poland, Argentina, France, Bulgaria, Denmark, United States, Brazil, Canada, Estonia, Georgi... and more
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1)

Chronic Obstructive Pulmonary Disease

Argentina, Chile, Mexico, Israel, Hungary, Russian Federation, Bulgaria, China, Czechia, Slovakia, Ukraine, United States, Romania, United Kingdom, Georgia, Greece, India, Italy, Mauritius, Poland, Taiwan
Regeneron Pharmaceuticals

Completed

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Healthy Volunteer

United Kingdom
Regeneron Pharmaceuticals

Completed

Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Homozygous Familial Hypercholesterolemia

United States, Netherlands, Canada
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) (ROXI-CATH)

Venous Thromboembolism

Israel, United States, Canada, Bulgaria, Romania
National Institute of Allergy and Infectious Diseases...

Completed

A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051

Corona Virus Infection

United States
Regeneron Pharmaceuticals

Completed

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Hypercholesterolemia

United States, Spain, Australia, Netherlands, Japan, Jordan, Denmark, Israel, Sweden, South Africa, Canada, Austria, Czechia, France, Italy, New Zealand, Norway, Poland, Russian Federation, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (CEREN1)

Chronic Rhinosinusitis With Nasal Polyps

Canada, Korea, Republic of, United Kingdom, United States, Chile
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (CEREN2)

Chronic Rhinosinusitis With Nasal Polyps

China, Canada, Australia, United Kingdom, United States, Chile
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps

Chronic Rhinosinusitis Without Nasal Polyps

Belgium, Canada, France, China, Korea, Republic of, Spain, Italy, United States, Argentina, Chile, Poland, Portugal, Romania
Regeneron Pharmaceuticals

Completed

A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants (ROXI-VTE II)

Venous Thromboembolism

Latvia, Lithuania, Hungary, Poland, Bulgaria
Regeneron Pharmaceuticals
Sanofi

Completed

Study of REGN3500 and Dupilumab in Patients With Asthma

Asthma, Allergic

United Kingdom, United States
Regeneron Pharmaceuticals

Completed

Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer

Cancer

United States
Regeneron Pharmaceuticals
Department of Health and Human Services

Completed

Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers

Healthy Volunteers

United States
Regeneron Pharmaceuticals

Available

R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease

Ebola Virus Disease
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

Asthma

Ukraine, United States, Argentina, Chile, Mexico, Poland, Russian Federation, Turkey
Sanofi
Regeneron Pharmaceuticals

Completed

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Ukraine, Argentina, Chile, Poland, Russian Federation, Turkey, United States, Australia, Canada, Germany
Regeneron Pharmaceuticals

Recruiting

Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants

Healthy Volunteers

United Kingdom

Search clinical trials for: REGN3500

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations